Filing Details
- Accession Number:
- 0000911916-17-000034
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-01-05 16:37:04
- Reporting Period:
- 2017-01-05
- Filing Date:
- 2017-01-05
- Accepted Time:
- 2017-01-05 16:37:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1348649 | Colucid Pharmaceuticals Inc. | CLCD | Pharmaceutical Preparations (2834) | 203419541 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1639978 | P. Thomas Mathers | C/O Colucid Pharmaceuticals, Inc. 222 Third Street Cambridge MA 02142 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-01-05 | 3,755 | $0.00 | 258,021 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-01-05 | 802 | $34.25 | 257,219 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-01-05 | 200 | $34.86 | 257,019 | No | 4 | S | Direct | |
Common Stock | Disposition | 2017-01-05 | 500 | $35.60 | 256,519 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Units | Disposition | 2017-01-05 | 3,755 | $0.00 | 3,755 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
105,147 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of CoLucid Pharmaceuticals, Inc. common stock.
- Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Mathers on August 19, 2016. The purpose of the plan was to sell shares of common stock in order to pay the taxesrelated to the settlement of the RSUs.
- Represents the sale of 802 shares in multiple transactions, ranging in price from $33.45 to $34.40 per share, resulting in a weighted average sale price of $34.2462. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- Represents the sale of 200 shares in multiple transactions, ranging in price from $34.50 to $35.225 per share, resulting in a weighted average sale price of $34.8625. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range.
- On May 5, 2015, the reporting person received 360,508 RSUs. Those RSUs vest as follows: 50% of the RSUs vested on November 5, 2015; 12.5% of the RSUs vested on May 5, 2016; and the remaining RSUs vest in a series of 36 successive equal monthly installments upon completion of each additional month of service.